Drug companies control news with $$$$ in ads The Deeper

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
100
Drug companies control news with $$$$ in ads

The Deeper Reason For Drug Ads On Television

https://www.naturalblaze.com/2018/03/deeper-r...ision.html

By Jon Rappoport

Television viewers are inundated with drug ads from Big Pharma. It’s a flood.

Have you ever heard of these drugs? Otezla, Xeljanz, Namzaric, Keytruda, Breo, Cosentyz? Not likely. If you have, do you know what conditions they treat? Highly unlikely. But there they are, splashed in commercials.

Why? Who is going to remember to ask their doctor whether these and other obscure meds are right for them?

What’s going on here?

The answer is: IT DOESN’T MATTER WHAT DRUGS ARE BEING ADVERTISED.

If Pharma can pay enough TOTAL money for ads, for ALL drugs, and dominate the allotted TV time for commercials, it can control the news—and that is exactly what it wants to do.

Pharmaceutical scandals are everywhere. Reporting on them, wall to wall, isn’t good for the drug business. However, as an industry ponying up billions of dollars for TV ads, Pharma can limit exposure and negative publicity. It can (and does) say to television networks: If you give us a hard time on the news, we’ll take our ad money and go somewhere else. Boom. End of problem.

Face it, the billions of dollars Pharma is paying for TV ads are a drop in the bucket, compared with its profits gained from selling the drugs. The ads are a good investment. As a bribe.

Control the news.

There is another reason for the insane flood of TV drug ads:

By their sheer number, they convince viewers that medical drugs (no matter what they are) are absolutely necessary.

Hour by hour, viewers numbly watch drug commercial after commercial. The overall message is: To keep illness from your door, to cure illness, to alleviate illness, you must take these medicines. THIS IS LIFE IN THE 21ST CENTURY. You’re all sick, and you need help, and this is the ONLY kind of help there is.

The drug companies could invent names of fake drugs that don’t even exist, advertise them in a cascade on television, with the same intent. DRUGS ARE AS VITAL TO LIFE AS WATER OR AIR.
But what about all those dire warnings of side effects from the drugs? By law, the companies must include them in their commercials. Well, the companies have calculated that, on balance, the stark, front-line, unending message of DRUGS, DRUGS, AND MORE DRUGS will outweigh the warnings in viewers’ minds.

If the television audience is nailed with the idea that they can’t escape; that their health always hangs in the balance; that dire illnesses are always waiting in the shadows to strike; that the slightest ache or pain could be a precursor to a crippling or fatal disease; and drugs are the only solution and protection—they’re going to overlook the warnings about side effects.

ALL IN ALL, DRUG ADS ARE NEWS.

That’s the approach. Pharma is blasting out 24/7 news asserting modern medicine’s central and commanding role in the life of every human.

It’s a gigantic and stupendous piece of mind control, but when did that ever stop tyrants from inventing reality for the masses?

Implicit in “ask your doctor if drug X is right for you,” is the message: “go to your doctor.” That’s the key. If the ads can put a viewer into the system, he will be diagnosed with something, and he’ll be given a drug for it.

So the drug ads are also promotions for doctors, who are the arbiters and the decision makers. Some kind of medical need (drugs) always exists—and the doctor will tell you what it is. And all patients should OBEY. Even if, in the process, they go broke.

Take the case of Opdivo, a drug that treats squamous non-small cell lung cancer. Cost? $12,500 a month. Patients on Medicare will pay $2500 a month out of their own pockets. And the result?

Wall St. Journal: “In the clinical study on which the Opdivo ad bases its claims, the drug extended median patient survival to 9.2 months from the start of treatment…”

The cancer patient pays $22,500 for nine months of survival, during which the suffering continues, and then he dies.

The ad isn’t mentioning THAT.

The ad relies on the doctor to convince the patient to go along with this lunatic program.

The author of two explosive collections, THE MATRIX REVEALED and EXIT FROM THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free emails at www.nomorefakenews.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UST Grabs Italdesign: Driving Future Mobility with AI

Updated Category News Views 2

UST's Strategic Move Into Automotive's Future Wake up and smell the coffee, because UST is shaking up the automotive scene. They've just pulled off a major play by grabbing a majority stake in Italdesign. If that doesn't scream the next leap forward for the auto world, I don't know what does. UST isn't just buying a company; it's marrying Italdesign's legendary design...

Continue Reading
Nuix Leverages AI for Transformative Legal Review

Updated Category News Views 1

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Continue Reading
Navimow Powers TOP 14 with Tech: A Winning Play

Updated Category News Views 0

A Technological Leap for French Rugby Innovation and precision in partnerships—those words don't usually pop up together when chatting about a rugby league. But here we are, discussing the TOP 14, the elite French rugby championship, pairing up with Segway Navimow. This brand, under the umbrella of Ninebot Limited (689009.SH), is stepping into the world of sports for...

Continue Reading
Rznomics Unveils Breakthrough in Circular RNA Production

Updated Category News Views 1

Decoding the RNA Revolution Ever heard of circular RNA (circRNA)? This ain't your typical strand of genetic code. Unlike their straight-laced, linear counterparts, these RNAs form a loop you can't just break. Picture them as the Kevlar vests of the RNA world—tough, resilient, and packing the promise of next-gen treatments in their covalent loops. Here we’ve got...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 3

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading
Ping An Climbs Sustainability Ladder, Scores A+ Rating

Updated Category News Views 2

Sustainability Triumph for Ping An: A+ Upgrade Ping An Insurance (Group) Company of China, Ltd. is having quite the moment, snagging an A+ in the latest 2026 Sustainability Rating from Hang Seng Indexes Company. This ain't just a one-time pat on the back—it's the third year of consecutive improvement. Looks like Ping An's focus on ESG efforts is finally getting the...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 2

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
CelluPro Earns Global Recognition with EXCiPACT Certification

Updated Category News Views 1

Breaking New Ground with EXCiPACT Certification Here's a tale unfolding in the high-stakes world of biotechnology—CelluPro, a standout in cell culture media, just snagged the EXCiPACT™ certification. This isn't just some fancy plaque for the wall. It's a stamp of approval that screams reliability in the global biomanufacturing supply scene. Why This Certification...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading

Top 5 Most Recently Viewed Articles

Alert: Red Cat Holdings Investors Consider Legal Action for Losses

Updated Category News Views 163

Overview of Recent Developments for Red Cat Holdings, Inc. Red Cat Holdings, Inc. (NASDAQ: RCAT) has been a topic of discussion among investors, particularly those who purchased securities within a designated period. Several developments have affected the company's stock price, creating an urgent situation for those who might have incurred financial losses. Company...

Continue Reading
Milestone Scientific Reports Strong Growth in Q3 Revenue

Updated Category News Views 128

Milestone Scientific Reports Impressive Revenue Growth for Q3 Addresses remarkable growth in international dental sales and ongoing expansion in pain management technology. Milestone Scientific Inc. (NYSE: MLSS), a forefront player in the development of advanced computerized drug delivery systems for precise and pain-free injections, has delivered promising financial...

Continue Reading
Rio Tinto's Plans for 7% Production Growth by 2025 Explained

Updated Category News Views 205

Rio Tinto's Strategic Overview Rio Tinto Plc (NYSE: RIO) has unveiled its ambitious strategy during a recent Capital Markets presentation aimed at achieving leading industry returns. The company is aligning its focus towards key commodities such as iron ore, copper, aluminium, and lithium, while ensuring heightened safety and productivity across all operations. Production...

Continue Reading
Understanding Elis's Capital Structure and Voting Rights Disclosure

Updated Category News Views 271

Overview of Elis's Capital Structure Elis is a prominent player in the service sector, particularly known for its textile and hygiene solutions. Recently, the company made an important disclosure concerning its capital structure and the total number of voting rights. This information is essential for shareholders and potential investors who wish to understand the...

Continue Reading
Bavarian Nordic Board Endorses Enhanced Takeover Offer

Updated Category News Views 235

Bavarian Nordic Board's Support for Increased Takeover Offer In a decisive move, the Board of Directors of Bavarian Nordic has reaffirmed its recommendation regarding the voluntary public takeover offer proposed by Innosera ApS. The consortium led by Nordic Capital and Permira is now offering an enhanced price for shareholders, marking a significant development for the...

Continue Reading